Kelly Boothe

Investor Relations Contact at Carmot Therapeutics, Inc.

Health Technology

Profile

Kelly Boothe is currently the Vice President of Investor Relations & Communications at Carmot Therapeutics, Inc. Prior to this role, Dr. Boothe worked as the Senior Director of Communications & Investor Relations at Spyre Therapeutics, Inc.

Kelly Boothe active positions

Companies	Position	Start
Carmot Therapeutics, Inc. Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA.	Investor Relations Contact	-

All active positions of Kelly Boothe

Former positions of Kelly Boothe

Companies	Position	End
SPYRE THERAPEUTICS, INC.	Investor Relations Contact	-

See the detail of Kelly Boothe's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Kelly Boothe's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
SPYRE THERAPEUTICS, INC.	Health Technology

Private companies	1
Carmot Therapeutics, Inc. Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA.	Health Technology